Hereditary angioedema (HAE) type 1 or type 2 Program in Pharmaceutical Benefits Scheme (PBS) 012-21112939

This document outlines details of PBS-subsidised lanadelumab for patients with hereditary angioedema (HAE) type 1 or 2.

For information on how to process a PBS Authority, see Processing Complex Authority Required Listings.

Restrictions	Authority level and section	PA assessment	Processing system	Prescriber type	Prescriber self-serve
Initial 1 New patient (commencing with no previous treatment with C1-INH for routine prophylaxis) PB325 form	Written Electronic S85: lanadelumab	No	OPA	Must be treated by a: Clinical immunologist Specialist allergist	Yes
Initial 2 New patient (commencing from National Blood Authority - funded C1-INH) PB325 form	Written Electronic S85: lanadelumab	No	OPA	Must be treated by a: Clinical immunologist Specialist allergist	Yes
Continuing Preventative treatment	Telephone Electronic S85: lanadelumab	No	OPA	Must be treated by a: Clinical immunologist Specialist allergist	Yes

Operational Information